Condition: Hematological Malignancies · Sponsor: Janssen Research & Development, LLC
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| University of Alabama Birmingham | Birmingham, Alabama, United States | Recruiting |
| University of Arkansas for Medical Sciences | Little Rock, Arkansas, United States | Recruiting |
| City of Hope | Duarte, California, United States | Completed |
| Memorial Healthcare System | Hollywood, Florida, United States | Recruiting |
| Emory University Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| University of Chicago | Chicago, Illinois, United States | Recruiting |
| Norton Cancer Institute | Louisville, Kentucky, United States | Recruiting |
| University of Michigan Health System | Ann Arbor, Michigan, United States | Recruiting |
| Washington University School Of Medicine | St Louis, Missouri, United States | Recruiting |
| NYU Langone Health | New York, New York, United States | Active Not Recruiting |
| Mount Sinai Medical Center | New York, New York, United States | Recruiting |
| University of Rochester Medical Center | Rochester, New York, United States | Recruiting |
+ 66 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04634552